A multicenter, randomized Phase I/II study evaluating the combination of luspatercept in patients with LR-MDS without RS who have failed or are ineligible for treatment with ESA.
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
The trial is being conducted to determine whether, at week 25 (i.e., after 6 months of treatment), Luspatercept plus ESA is superior and more effective than Luspatercept alone.
Low-risk myelodysplastic syndrome without relapse
Pathologies
Onco-hematological (hematological cancers/malignancies)
Medication
Luspatercept vs. Luspatercept + ESA
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with LR-MDS who have failed or are ineligible for treatment with ESA.
Back to search page